

L2 ANSWER 500 OF 771 USPATFULL on STN  
ACCESSION NUMBER: 2001:4474 USPATFULL  
TITLE: Method of making and binding CAIP polypeptides  
INVENTOR(S): Hsu, Yen-Ming, Lexington, MA, United States  
PATENT ASSIGNEE(S): Biogen, Inc., Cambridge, MA, United States (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6171800	B1	20010109
APPLICATION INFO.:	US 1995-474697		19950607 (8)
DOCUMENT TYPE:	Patent		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Spector, Lorraine		
ASSISTANT EXAMINER:	Kaufman, Claire M.		
LEGAL REPRESENTATIVE:	Fish & Richardson P.C.		
NUMBER OF CLAIMS:	42		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 7 Drawing Page(s)		
LINE COUNT:	2252		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD The inventor has discovered novel peptides that specifically interact with the CD2 intracellular domain and has provided a core physical structure having the ability to bind CD2 intracellular domain and to downstream intracellular protein. Once an example of this core structure has been provided one skilled in the art can alter the disclosed structure (of CAIP or CD2), e.g., by producing fragments or analogs, and test the newly produced structures for activity. Examples of prior art methods which allow the production and testing of fragments and analogs are discussed below. These, or analogous methods can be used to make and **screen** fragments and **analog**s of a CAIP-like polypeptide, e.g., a CAIP polypeptide, which bind CD2, or of a downstream intracellular **protein**. Likewise they can be used to make fragments and analogs of CAIP-like polypeptide ligands, e.g., CD2, which bind a CAIP-like polypeptide.

DETD Two hybrid assays such as the system described above (as with the other screening methods described herein), can be used to identify fragments or analogs of a CAIP polypeptide which binds to the intracellular domain of CD2. These may include agonists, superagonists, and antagonists. (The CD2 domain is used as the bait **protein** and the library of variants are expressed as fish fusion **proteins**.) In an **analogous** fashion, a two hybrid assay (as with the other **screening** methods described herein), can be used to find fragments and **analog**s of CD2 which bind a CAIP polypeptide.

=>